A. B. Van-kuilenburg, Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5fluorouracil, Eur J Cancer, vol.40, pp.939-950, 2004.

M. Tsalic, G. Bar-sela, and A. Beny,

, fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients, Am J Clin Oncol, vol.26, pp.103-106, 2003.

D. Meulendijks, L. M. Henricks, and B. Jacobs, Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity, Br J Cancer, vol.116, pp.1415-1424, 2017.

R. P. Marques, G. S. Duarte, and C. Sterrantino, Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis, Crit Rev Oncol Hematol, vol.118, pp.54-62, 2017.

M. A. Loriot, J. Ciccolini, and F. Thomas, Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks

, Bull Cancer, vol.105, pp.397-407, 2018.

D. Meulendijks, A. Cats, and J. H. Beijnen, Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity-Ready for clinical practice?, Cancer Treat Rev, vol.50, pp.23-34, 2016.

M. Boisdron-celle, L. Guellec, C. , and S. Therapeutique,

, Therapie, vol.65, pp.171-176, 2010.

R. F. Murphy, F. M. Balis, and D. G. Poplack, Stability of 5-fluorouracil in whole blood and plasma, Clin Chem, vol.33, pp.2299-2300, 1987.

E. Gamelin, A. L. Bouil, and M. Boisdron-celle, Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients, Clin Cancer Res, vol.3, pp.891-899, 1997.

P. Deng, C. Ji, and X. Dai, Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatographytandem mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci, vol.989, pp.71-79, 2015.

D. Montange, M. Berard, and M. Demarchi, An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma, J Mass Spectrom, vol.45, pp.670-677, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00508032

O. Chavani, B. P. Jensen, and R. M. Strother, Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil

, ureidopropionic acid and alpha-fluoro-beta-alanine in human plasma, J Pharm Biomed Anal, vol.142, pp.125-135, 2017.

J. H. Beumer, M. Boisdron-celle, and W. Clarke, Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer, Ther Drug Monit, vol.31, pp.688-694, 2009.